Protein Requirements in Children With Phenylketonuria (PKU)

Status Completed

Clinical Trial Summary

Phenylketonuria (PKU) is an inherited inborn error of an amino acid phenylalanine (PHE) metabolism affecting 1:15,000 births. It is caused by a decreased activity of an enzyme in the liver called phenylalanine hydroxylase (PAH) which is important to convert PHE into tyrosine, another amino acid. Consequently, PHE accumulates in the blood leading to mental and developmental delays. Nutritional management is the primary choice of treatment that includes providing sufficient protein in the diet and at the same time restricting PHE. However the amount of protein to be given is unknown. A new technique called Indicator Amino Acid Oxidation (IAAO) will be used to determine the protein requirements in children with PKU (5-18y). The study will help treat and manage these children with sufficient protein to ensure proper growth and development. Current dietary recommendations range from 35-65 g/day and is based on factorial calculations.

The investigators hypothesize that the protein requirement in children with PKU will be higher than the current mathematically calculated recommended intake of 35-65 g/day for the 5-18y children.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01965691
Study type	Interventional
Source	University of British Columbia
Contact
Status	Completed
Phase	N/A
Start date	October 2013
Completion date	December 2015

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05099640` - A Study of PTC923 in Participants With Phenylketonuria	Phase 3
Completed	`NCT01924026` - Neurocognitive Outcomes in Mild Hyperphenylalaninemia (MHP)MHP Study	N/A
Completed	`NCT01428258` - Phase 2 Study of Glycomacropeptide Versus Amino Acid Diet for Management of Phenylketonuria	N/A
Completed	`NCT00925054` - Dose-Finding Study to Evaluate the Safety, Efficacy, & Tolerability of Multiple Doses of rAvPAL-PEG in Subjects With PKU	Phase 2
Completed	`NCT00778206` - PKUDOS: Phenylketonuria (PKU) Demographic, Outcomes, and Safety Registry
Recruiting	`NCT05948020` - Efficacy and Safety of Orally Administered Engineered Probiotics (CBT102-A) for the Treatment of Children With Phenylketonuria	N/A
Recruiting	`NCT05781399` - First-in-Human, Multiple Part Clinical Study of JNT-517 in Healthy Participants and in Participants With Phenylketonuria	Phase 1
Completed	`NCT02555579` - Simplified Diet Approach in Phenylketonuria	N/A
Completed	`NCT03097250` - MRI Spectroscopy and Neuropsychological Functioning in Phenylketonuria
Completed	`NCT01965912` - Kuvan®'s Effect on the Cognition of Children With Phenylketonuria	Phase 4
Completed	`NCT00688844` - Nutritional and Neurotransmitter Changes in PKU Subjects on BH4	N/A
Completed	`NCT00789568` - A Phase 1 Study to Evaluate Effects of Sapropterin Dihydrochloride on QTc Intervals in Healthy Adult Subjects	Phase 1
Terminated	`NCT01465100` - Liver Cell Transplant for Phenylketonuria	Phase 1/Phase 2
Completed	`NCT01732471` - Phase 3 Open-label Study to Evaluate the Response and Safety of Kuvan® in Subjects With Phenylketonuria	Phase 3
Completed	`NCT04879277` - Study of Low-grade Systemic Inflammation in Adult Patients With Phenylketonuria	N/A
Completed	`NCT02176603` - Observational Study of Endothelial Dysfunction in Phenylketonuria	N/A
Completed	`NCT01869972` - Biological Variation of Phenylalanine in Patients With Hyperphenylalaninemia	N/A
Completed	`NCT01819727` - An Open-Label Phase 3 Study of BMN 165 for Adults With PKU Not Previously Treated w/ BMN 165	Phase 3
Terminated	`NCT01904708` - Moderate Intensity Exercise and Phenylketonuria	N/A
Completed	`NCT01560286` - A Study to Evaluate Subcutaneously Administered rAvPAL-PEG in Patients With Phenylketonuria for 24 Weeks	Phase 2